NCIt definition : A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two
single-chain variable fragments (scFv), one directed against the tumor-associated
antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and
one that is directed against the CD3 antigen found on T-lymphocytes, with potential
immunostimulating and antineoplastic activities. Upon administration of cevostamab,
the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs)
and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs
with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of
FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc
receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed
on myeloma cells.;
Semantic type(s)